The ENHANCE study is a Phase 4 clinical trial designed to evaluate the real-world safety and effectiveness of ELEVIDYS in patients with Duchenne muscular dystrophy (DMD).
This study is particularly important because it focuses on patients treated in a post-marketing setting, meaning after the therapy has already been approved and is being used in clinical practice.
The trial is sponsored by Sarepta Therapeutics and carries the study ID SRP-9001-402.
Table of Contents
Primary Goal: Understanding Liver Safety Risks
Why Liver Safety Matters
One of the main concerns with gene therapies like ELEVIDYS is the risk of acute liver injury (ALI).
Role of Sirolimus
The study evaluates whether adding sirolimus as a preventive (prophylactic) immunosuppressive treatment can help reduce liver-related complications.
In simple terms:
- ELEVIDYS helps deliver a functional dystrophin gene.
- Sirolimus helps control the immune system’s reaction to the therapy.
- The goal is to make treatment safer without reducing effectiveness.
Study Design and Key Details
Trial Overview
- Study Type: Interventional
- Phase: Phase 4
- Estimated Enrollment: 20 participants
- Start Date: April 30, 2026
- Completion Date: March 31, 2027
Study Groups (Cohorts)
The trial includes two participant groups:
Cohort 1:
- Boys aged 4 years and older
- Must be ambulatory (able to walk)
- Eligible for commercial ELEVIDYS treatment
Cohort 2:
- Previously treated with ELEVIDYS
- Already received sirolimus and corticosteroids before therapy
Who Can Participate?
Key Inclusion Criteria
Participants must:
- Be male at birth
- Meet age and treatment eligibility requirements
- Have a caregiver or be able to follow study procedures
- Provide informed consent (or have a legal guardian do so)
- Use appropriate birth control if sexually active
Who Cannot Participate?
Key Exclusion Criteria
Participants may not join if they:
- Cannot safely receive ELEVIDYS
- Have infections such as:
- HIV
- Hepatitis B or C
- Have recent infections or vaccinations
- Have conditions that could affect safety or study results
- Cannot tolerate sirolimus
- Have wounds or injuries that may heal poorly under immunosuppression
Why This Study Is Important for the DMD Community
Real-World Evidence
Unlike earlier trials, this study reflects real-life treatment conditions, helping doctors understand:
- How safe ELEVIDYS is outside controlled environments
- How patients respond over time
Improving Treatment Safety
If successful, the study may:
- Reduce liver-related risks
- Improve treatment protocols
- Increase confidence in gene therapy use
Contact Information
For more details about the study:
- Organization: Sarepta Therapeutics
- Phone: 1-888-SAREPTA (1-888-727-3782)
- Email: [email protected]
Clinical Trial Locations Not Yet Announced
The locations for the ENHANCE clinical trial have not yet been publicly disclosed. The study sponsor, Sarepta Therapeutics, is expected to announce participating sites at a later stage. Patients, caregivers, and healthcare professionals are encouraged to monitor official updates as site information becomes available.
Follow This Page >>> All Clinical Trials for Duchenne
